Background: Basidiobolomycosis, which is caused by pathogenic Basidiobolus species, is a rare fungal infection affecting the skin and gastrointestinal tract, which is mainly reported from tropical and subtropical regions. There is evidence that 'unconventional' antifungal drugs affect some fungal species. The current study intended to assess the in vitro effect of non-antifungal drugs, namely, artesunate, chloramphenicol, and co-trimoxazole in comparison to amphotericin B, fluconazole, itraconazole, metronidazole, and voriconazoleon in comparison to amphotericin B, fluconazole, itraconazole, metronidazole, and voriconazoleon on representative medically significant fungi. Methods: Basidiobolus species (n =13) isolated from human gastrointestinal basidiobolomycosis and lizards were tested against artesunate, chloramphenicol, and co-trimoxazole. The antimicrobial assay was done using the agar diffusion method. The broth microdilution method was performed with a two-fold serial dilution of each antimicrobial agent to determine the minimum inhibitory concentration (MIC). The nonparametric Wilcoxon Signed Rank Test. analyzed the mean difference between inhibitory measures between the drugs. Results: The three agents exhibited inhibitory actions against Basidiobolus species comparable to the known antifungals. The combined effects of artesunate + voriconazole and co-trimoxazole + voriconazole have significant synergic effects, p = 0.003 and p = 0.021, respectively. Conclusions: This study showed that non-antifungal agents were active against Basidiobolus species. These are promising results that enhance the accelerated combined treatment of GIB in humans, particularly the combination of artesunate and voriconazole.